RxDoctor Payments Data

Maria Cortti Ferrari, MD

Nephrology · Plantation, FLNPI 1639434236

Payments from drug & device makers

$1,425in general payments, 2019–2025

Across 68 payments — averaging $20.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Exact Sciences$348
  • Boehringer Ingelheim$266
  • Amgen$207
  • Novo Nordisk$147
  • Bayer$135
  • Otsuka America Pharmaceutical, Inc.$106
  • plus $216 from 6 others

What the payments were for

  • Food & beverage$1,425100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,425 in reported general payments places this provider in the 40th percentile of 756 nephrology providers in Florida.

See all nephrology providers in Florida

Medicare billing

Part B allowed, 2024
$13,661
Medicare patients
28
Services billed
142

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide21$21,984
MounjaroTirzepatide18$18,483
JardianceEmpagliflozin13$17,049
OzempicSemaglutide11$10,256
Lantus SolostarInsulin Glargine,hum.Rec.Anlog20$2,502
Atorvastatin Calcium257$1,828
Nifedipine ErNifedipine88$1,589
Levothyroxine Sodium111$1,102
Valsartan44$1,029
Albuterol Sulfate HfaAlbuterol Sulfate30$981
Rosuvastatin Calcium87$981
Losartan Potassium131$853
Torsemide37$646
Olmesartan Medoxomil54$595
Lisinopril112$487

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$39$40,46739 claims
Boehringer IngelheimJardiance$266$17,04913 claims
Novo NordiskOzempic$147$10,25611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 756 nephrology providers in Florida.

Other nephrology in Plantation

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →